ClinicalTrials.gg
WithdrawnNCT05371275CDK6COVUpdated Nov 7, 2022

Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

A Phase 2 interventional study of Palbociclib in COVID-19, sponsored by biotx.ai GmbH. Withdrawn at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by biotx.ai GmbH · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was withdrawn due to challenges in patient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.

Enrollment
126th of 130
0 · median 135
Started
2022
with 35 others
Phase 2
28 of 226
none open now
Registered
185th of 226
by date

Among the 226 studies in COVID-19 with a site in Germany, this one is the 126th largest by enrollment of the 130 interventional ones that give a count, is one of 36 that started in 2022, is one of 28 in phase 2, and was the 185th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in COVID-19 with a site in Germany, or all of them as a file.
02

Study summary

This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.

Read the detailed description

The study will include hospitalized, moderate COVID-19 cases that have a risk of respiratory failure.

The study will generally consist of:

  • A short screening phase (1 day) before enrollment and thus treatment decision.
  • A 21 day treatment phase with one "cycle" of palbociclib
  • An up to day 90 Safety Follow-Up Phase

The first three patients will be enrolled and treated one by one; the independent safety data review committee (ISRC) will review each patient after D21 before enrollment of the subsequent patient is permitted.

03

Conditions studied

  • COVID-19

Keywords

  • COVID-19
  • moderate
  • hospitalized
  • Palbociclib
  • CDK4/6 inhibition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age >= 18 years
  2. positive PCR COVID-19 test (max. 72h old)
  3. known vaccination status
  4. >= 1,000/mm3 and >= 50,000/mm3
  5. willingness to participate (written )
  6. established risk factors for a severe course of COVID-19-disease, for example: adipositas, cardiovascular disease including arterial hypertension, advanced age > 60, chronic lung disease including asthma, diabetis type I or II, chronic kidney disease, chronic liver disease
  7. Oxygen supply: ≤ 2 liters/minute
  8. Women of (WOCBP): must have a negative pregnancy test (ß- HCG urine or serum test) a. WOCBP is considered as i.e. fertile, following menarche and until becoming unless permanently sterile.

    b. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

    c. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

  9. Use of highly effective method

    1. All potentially fertile participants, or their male partners, must use an adequate, medically approved method of contraception or agree to abstinence during and at least 3 weeks (females) and 14 weeks (males) after treatment with Palbociclib.
    2. For females, highly effective birth control should be used, i.e., combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, or intrauterine hormone-releasing system, bilateral tubal occlusion and vasectomized partner. As there is no information available on the interaction of palbociclib with oral contraceptives, a double-barrier contraception is necessary in this case.
    3. Males must agree to use a condom for at least 14 weeks after the treatment phase.

Exclusion criteria

Exclusion Criteria:

  1. age \< 18 year
  2. >= 3
  3. ANC \< 1,000/mm3 and \< 50,000/mm3
  4. intensive care patient
  5. treatment with any other CDK4/6 Inhibitor
  6. pregnant or breast-feeding women
  7. patients receiving for other diseases (e.g. rheumatoid arthritis)
  8. known in the past 5 years other than basal cell carcinoma
  9. baseline O2-Saturation \< 92%
  10. participation in any other medical device or medicinal product study within the previous month
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Palbociclib

    125 mg of palbociclib once daily for 21 consecutive days

    Drug: Palbociclib

Interventions

  • 125 mg of palbociclib once daily for 21 consecutive days

06

What researchers measure

Primary outcomes

  1. Rate of treatment-related treatment discontinuation after 21 days of palbociclib treatment

    Time frame: 21 days

Secondary outcomes

  1. Time to freedom from oxygenation, measured in days after the first treatment dose.

    Time frame: 90 days

  2. Time to transfer to ICU

    Time frame: 90 days

  3. Course of neutrophil cell count during treatment

    Time frame: 21 days

  4. Course of D-dimer during treatment

    Time frame: 21 days

  5. Rate of thrombotic events during treatment

    Time frame: 21 days

  6. Course of O2 saturation during treatment

    Time frame: 21 days

  7. Rate of persisting symptoms after 3, 6, 9 and 12 months

    Time frame: Through completion of safety follow-up up to 12 month

  8. Dose reduction rate

    Time frame: 21 days

  9. Rate of (S)AEs at day 21

    Time frame: at day 21

07

Study locations

1 site
  • Universitätsklinikum Brandenburg an der Havel
    Brandenburg an der Havel, 14770, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Oct 2022, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2022
First posted
May 12, 2022
StartActual
Apr 21, 2022
Primary completionEst.
Oct 2022
CompletionEst.
Dec 2022
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05371275
Lead sponsor
biotx.ai GmbH
Responsible party
Sponsor
First posted
May 12, 2022
Start date
Apr 21, 2022
Primary completion
Oct 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Nov 7, 2022

Study contacts

Mark Reinwald, PD Dr. med.
principal investigator · Universitätsklinikum Brandenburg an der Havel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion